Literature DB >> 23740336

Current topics in opioid therapy for pain management: addressing the problem of abuse.

Frank E Casty1, Matthew S Wieman, Neil Shusterman.   

Abstract

Opioids are an established therapy for cancer pain and have become an accepted therapy for chronic noncancer pain. However, increased prescribing of opioids in recent years has been accompanied by an increase in prescription opioid abuse. All opioids have inherent potential for abuse, but gaps in healthcare provider understanding of or adherence to best prescribing practices may facilitate the misdirection of opioids for abuse. To address these concerns, the US Food and Drug Administration has required pharmaceutical manufacturers to develop Risk Evaluation and Mitigation Strategies (REMS) for prescribers of extended-release/long-acting (ER/LA) opioids and has encouraged research to develop opioid formulations that are less easily abused or less attractive for abuse. The ER/LA opioid REMS require a partnership between the pharmaceutical industry, regulators, and healthcare providers to develop educational materials for physicians and patients that are not promotional. This article addresses challenges associated with improving the quality of pain care through support of prescriber education, developing formulations that combine efficacy with tamper-resistant properties, and encouraging collaborative efforts by regulatory bodies, legislators, healthcare providers, and patient advocacy groups to achieve these ends.

Entities:  

Mesh:

Year:  2013        PMID: 23740336     DOI: 10.1007/s40261-013-0087-8

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  19 in total

1.  Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.

Authors:  Lynn R Webster; Randall Brewer; Chao Wang; Doreen Sekora; Franklin K Johnson; David Morris; Joseph Stauffer
Journal:  J Pain Symptom Manage       Date:  2010-11       Impact factor: 3.612

Review 2.  Abuse-deterrent opioid formulations: are they a pipe dream?

Authors:  Nathaniel Katz
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

3.  Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.

Authors:  Kieran A Slevin; Michael A Ashburn
Journal:  J Opioid Manag       Date:  2011 Mar-Apr

4.  Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery.

Authors:  S S Reuben; N R Connelly; H Maciolek
Journal:  Anesth Analg       Date:  1999-06       Impact factor: 5.108

5.  Evaluating the impact of pain management (PM) education on physician practice patterns--a continuing medical education (CME) outcomes study.

Authors:  L Leong; J Ninnis; N Slatkin; M Rhiner; L Schroeder; B Pritt; J Kagan; T Ball; R Morgan
Journal:  J Cancer Educ       Date:  2010-03-05       Impact factor: 2.037

6.  Survey of Ontario primary care physicians' experiences with opioid prescribing.

Authors:  Elizabeth Francis Wenghofer; Lynn Wilson; Meldon Kahan; Carolynn Sheehan; Anita Srivastava; Ava Rubin; Joanne Brathwaite
Journal:  Can Fam Physician       Date:  2011-03       Impact factor: 3.275

7.  Opioid extended-release tablets with improved tamper-resistant properties.

Authors:  Johannes H Bartholomaeus; Elisabeth Arkenau-Marić; Eric Galia
Journal:  Expert Opin Drug Deliv       Date:  2012-06-13       Impact factor: 6.648

8.  Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.

Authors:  Derry Ridgway; Maciej Sopata; Arvydas Burneckis; Lillian Jespersen; Christine Andersen
Journal:  J Pain Symptom Manage       Date:  2010-04       Impact factor: 3.612

9.  Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care setting.

Authors:  James Brown; Beatrice Setnik; Keung Lee; Linda Wase; Carl L Roland; Jody M Cleveland; Sherry Siegel; Nathaniel Katz
Journal:  J Opioid Manag       Date:  2011 Nov-Dec

10.  Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report.

Authors:  Charles Grudzinskas; Robert L Balster; Charles W Gorodetzky; Roland R Griffiths; Jack E Henningfield; Chris-Ellyn Johanson; Robert S Mansbach; Cynthia G McCormick; Sidney H Schnoll; Eric C Strain; C Wright
Journal:  Drug Alcohol Depend       Date:  2006-03-31       Impact factor: 4.492

View more
  5 in total

1.  Opioid misuse behaviors in adolescents and young adults in a hematology/oncology setting.

Authors:  Jennifer Harman Ehrentraut; Kathleen Danielle Kern; Sarah A Long; Angel Qi An; Lane G Faughnan; Doralina L Anghelescu
Journal:  J Pediatr Psychol       Date:  2014-09-14

Review 2.  The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Authors:  Nalini Vadivelu; Erika Schermer; Gopal Kodumudi; Jack M Berger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 3.  Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.

Authors:  Nalini Vadivelu; Daniel Chang; Leandro Lumermann; Thomas Suchy; Matthew M Burg; Manuel L Fontes
Journal:  Curr Pain Headache Rep       Date:  2017-02

4.  Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy.

Authors:  Joshua C Black; Gabrielle E Bau; Travis Rosen; M Soledad Cepeda; Gregory P Wedin; Jody L Green; Richard C Dart
Journal:  Pain Med       Date:  2020-01-01       Impact factor: 3.750

5.  A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.

Authors:  Lynn R Webster; Ernest A Kopecky; Michael D Smith; Alison B Fleming
Journal:  Pain Med       Date:  2015-12-14       Impact factor: 3.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.